Avantor acquires RIM Bio, expands bioproduction footprint into China

Changzhou, China, operations become Avantor's first single-use production facility in AMEA region; doubles Avantor's global single-use cleanroom space

0
26
Avantor’s acquisition of RIM Bio and its proprietary technology provides single use bioprocess customers with differentiated product offerings
New Delhi: Avantor, Inc, a leading global provider of mission-critical products and services to customers in the life sciences has acquired RIM Bio, a leading China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications.
RIM Bio’s Changzhou, China, facility is Avantor’s first single-use production plant in the AMEA region, building on the company’s existing global single-use manufacturing network in the Americas and Europe and greatly increasing capacity to meet growing global demand in bioprocessing. Avantor will leverage RIM Bio’s proprietary technologies and best-in-class lead times to provide single-use customers with a differentiated offering.
Dr Ger Brophy, Executive Vice President, Biopharma Production at Avantor, said, “Adding RIM Bio enables Avantor to better serve our customers by expanding our single-use manufacturing, distribution, and cleanroom capabilities to the AMEA region. RIM serves as an anchor for us to build our presence in this key region, as we better position Avantor to capture long-term opportunities in the growing, global Bioproduction space.”
Established in 2009, RIM Bio provides a complete range of single-use 2D bags, 3D bags, tank liners, bag assemblies and multi-bag manifolds used in the manufacturing of biologics including monoclonal antibodies (mAbs), vaccines, cell and gene therapies, and recombinant proteins.
This acquisition marks another major investment in China. In December 2019, the company opened its Shanghai Innovation & Customer Support center, a dedicated bioprocessing facility focused on research, application development and process optimization solutions for biopharma companies across AMEA.